Cinacalcet (AMG-073) HCl

For research use only.

Catalog No.S1260

5 publications

Cinacalcet (AMG-073) HCl Chemical Structure

CAS No. 364782-34-3

Cinacalcet (AMG-073) HCl represents a new class of compounds for the treatment of hyperparathyroidism.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 160 In stock
USD 120 In stock
USD 390 In stock
USD 670 In stock
USD 1217 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Cinacalcet (AMG-073) HCl has been cited by 5 publications

3 Customer Reviews

  • Effects of intra-synovial injections of CaSR antagonist (NPS2143) and agonist (Cinacalcet) on morphology (A) in rat TMJ cartilage without (Control) or with UAC stimulation. Test compounds (50 μL of 100 nM stock) and vehicle injections were performed on 10‐week‐old rats every other day for 4 weeks. UAC began 4 weeks before drug injections and continued for another 4 weeks during drug treatments. (A) Safranin O staining (in red) showed the ability of NPS2143 to increase proteoglycan content and thickness of TMJ cartilage and decreased OA grade, the ability of Cinacalcet to suppress these parameters in both control and UAC groups when compared with corresponding vehicle‐injected group. Scale bar = 100 µm. n = 6 rats per group.

    J Bone Miner Res, 2018, doi:10.1002/jbmr.3643. Cinacalcet (AMG-073) HCl purchased from Selleck.

    A. SK-N-LP cells stably transfected with pCMV-GFP or pCMV-CaSR-GFP were grown in serum deprivation media for 16 hours. They were then exposed to cinacalcet for 24 hours at indicated doses in the same media containing 0.5 mM CaCl2 . Total proteins were isolated from floating and adherent cells to conduct immunoblots.

    Oncotarget, 2016, 7(13):16112-29. Cinacalcet (AMG-073) HCl purchased from Selleck.

  • Cells were exposed to vehicle or cinacalcet 2 μM for 2 and 16 h (A and B) either alone (white bars) or adding CQ 20 μM (gray bars) for the last 3 h. Each panel shows a representative image of LC3II and β-actin (internal loading control) and the respective densitometry analysis. Bars represent mean ± SEM of 5–7 independent experiments. *p < 0.05 vs. all other conditions. Two-way ANOVA and Tukey's post hoc test for multiple comparisons.

    Biochim Biophys Acta Mol Basis Dis, 2018, 1864(11):3585-3594. Cinacalcet (AMG-073) HCl purchased from Selleck.

Purity & Quality Control

Choose Selective CaSR Inhibitors

Biological Activity

Description Cinacalcet (AMG-073) HCl represents a new class of compounds for the treatment of hyperparathyroidism.
CaSR [1]
2.8 μM(EC50)
In vitro

AMG-073 represents a new class of compounds for the treatment of hyperparathyroidism known as calcimimetics, which reduce parathyroid hormone (PTH) synthesis and secretion by increasing the sensitivity of the parathyroid calcium-sensing receptor (CaR) to extracellular calcium. AMG-073 has potential advantages as a therapy for secondary hyperparathyroidism because it mimics the effects of extracellular calcium to suppress PTH secretion, even in the presence of hyperphosphatemia, without the risk of causing hypercalcemia and/or hyperphosphatemia. AMG-073 produces a concentration-dependent increase in cytoplasmic calcium in human embryonic kidney cells expressing the CaSR. In bovine parathyroid cells and a buffer containing calcium 0.5 mM, AMG 073 (3 nM – 1 μM) produces a concentration-dependent decrease in PTH levels with IC50 of 27 nM. [2]

In vivo AMG-073 orally administrated to normal rats at dose of 1, 3, 10, and 30 mg/kg in 20% sulfobutyl ether β-cyclodextrin sodium produces a significant dose-dependent reduction in PTH levels for 1 to 4 hours after administration. At 8 hours, the 10- and 30-mg/kg doses of AMG-073 produces significant reductions in PTH levels compared with controls that disappears by 24 hours. Significant dose-dependent reduction in serum calcium levels are observed at 4, 8, and 24 hours after oral administration of AMG-073 3, 10, and 30 mg/kg, respectively. A transient reduction in serum phosphorus levels is observed only with the highest dose of AMG-073. In addition, increased calcitonin levels that paralleled PTH suppression are observed with AMG-073 40 mg/kg in rats. As in normal rats, a rapid dose-dependent reduction in PTH and calcium levels is observed in 5 of 6 nephrectomized rats after oral administration of AMG-073. In addition, oral AMG-073 at 5 and 10 mg/kg for 4 weeks significantly reduces parathyroid weight compared with controls. [2]


Solubility (25°C)

In vitro DMSO 79 mg/mL (200.57 mM)
Water Insoluble
Ethanol '33 mg/mL
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 393.87


CAS No. 364782-34-3
Storage powder
in solvent
Synonyms N/A
Smiles CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03123406 Completed Drug: Cinacalcet HCl Hyperparathyroidism; Secondary Renal Kyowa Hakko Kirin China Pharmaceutical Co. LTD. April 19 2017 Phase 4
NCT02341417 Completed Drug: Cinacalcet Secondary Hyperparathyroidism Chronic Kidney Disease Amgen June 10 2015 Phase 3
NCT01748812 Terminated Drug: Osteomalacia Osteomalacia National Institute of Dental and Craniofacial Research (NIDCR)|National Institutes of Health Clinical Center (CC) November 16 2012 Phase 1
NCT01599962 Completed Drug: Cinacalcet|Drug: Placebo Memory Functions Prof. Dominique de Quervain MD|Clinical Trial Unit University Hospital Basel Switzerland|University of Basel March 2012 Phase 2
NCT01519037 Completed Drug: Cinacalcet 60 MG|Drug: Placebo oral tablet Relationship Between Calcimimetic and the RAAS Centre Hospitalier Universitaire Vaudois|Swiss National Science Foundation January 2012 Not Applicable

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

CaSR Signaling Pathway Map

Related CaSR Products

Tags: buy Cinacalcet (AMG-073) HCl | Cinacalcet (AMG-073) HCl ic50 | Cinacalcet (AMG-073) HCl price | Cinacalcet (AMG-073) HCl cost | Cinacalcet (AMG-073) HCl solubility dmso | Cinacalcet (AMG-073) HCl purchase | Cinacalcet (AMG-073) HCl manufacturer | Cinacalcet (AMG-073) HCl research buy | Cinacalcet (AMG-073) HCl order | Cinacalcet (AMG-073) HCl mouse | Cinacalcet (AMG-073) HCl chemical structure | Cinacalcet (AMG-073) HCl mw | Cinacalcet (AMG-073) HCl molecular weight | Cinacalcet (AMG-073) HCl datasheet | Cinacalcet (AMG-073) HCl supplier | Cinacalcet (AMG-073) HCl in vitro | Cinacalcet (AMG-073) HCl cell line | Cinacalcet (AMG-073) HCl concentration | Cinacalcet (AMG-073) HCl nmr
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID